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ABSTRACT
Background and aims: Chronic obstructive pulmonary disease
(COPD) is currently the 5th cause of morbidity and mortality in
the developed world and represents a substantial economic
and social burden. The aim of this study is to report on hospital
admissions and related costs of hospital treatment for COPD in
the Puglia Region of Italy in the years 2005-2007.
Materials and methods: Patients were selected who were hospi-
talized between 01/01/2005 and 31/12/2007 with ICD-9-CM
code: 490.xx: bronchitis not specified as acute or chronic;
491.xx: chronic bronchitis; 492.xx: emphysema; 493.xx: asthma;
494.xx: bronchiectasis; 496.xx: chronic airway obstruction not
elsewhere classified; 518.81: acute respiratory failure as princi-
pal or secondary diagnosis. 
Results: In the period 2005-2007, there were 73,721 hospital
admissions for COPD registered in Puglia (25,690 in 2005;
24,153 in 2006 and 23,878 in 2007) of which 34.3% were
women, with no significant variation in the three years. There
appears to be a negative trend in hospitalisations in Puglia for
chronic bronchitis with ratios decreasing from 359.4 per
100,000 population in 2005 to 307.9 per 100,000 in 2007. The
overall cost of COPD for Apulian hospital trusts was
€272,293,182.85 over the 3-year period. 
Conclusions: Analysis of the data for hospital care, its costs and
performance may be an important indicator of the efficacy of
community care. In particular, the lack of reduction in admis-
sions for COPD should lead decision makers to question both
the appropriateness and quality of the care given.
Keywords: COPD, epidemiology, health information systems,
primary care.
RIASSUNTO 
Razionale e scopo: La broncopneumopatia cronica ostruttiva
(BPCO) è al momento attuale la quinta causa di mortalità e
morbilità nel mondo sviluppato e comporta un notevole im-
patto sociale ed economico. Scopo di questo studio è analiz-
zare le ospedalizzazioni e i costi relativi al trattamento ospe-
daliero della BPCO nella regione Puglia negli anni 2005-2007.
Materiali e metodi: Sono stati selezionati i pazienti ospedaliz-
zati tra 01/01/2005 e 31/12/2007 con i segenti codici ICD-9-
CM: 490.xx: bronchite non specificata se acuta o cronica;
491.xx: bronchite cronica; 492.xx: enfisema; 493.xx: asma;
494.xx: bronchiettasie; 496.xx: ostruzione cronica delle vie
aeree; 518.81: insufficienza respiratoria acuta come diagnosi
principale o secondaria. 
Risultati: Nel periodo 2005-2007 sono state registrate 73.721
ospedalizzazioni per BPCO in Puglia (25.690 nel 2005; 24.153
nel 2006 e 23.878 nel 2007), il 34,3% erano donne, senza va-
riazioni significative nei tre anni. Il trend delle ospedalizzazio-
ni per bronchite cronica in Puglia pare essere negativo, con
tassi in riduzione da 359,4 ogni 100.000 abitanti nel 2005 a
307,9 ogni 100.000 nel 2007. Il costo complessivo della 
BPCO per gli enti ospedalieri pugliesi è stato pari a
€272.293.182,85 nel periodo di 3 anni. 
Conclusioni: L’analisi dei dati sul trattamento ospedaliero, i
suoi costi e le sue performance può essere un indicatore di ri-
lievo dell’efficacia del trattamento sul territorio. In particola-
re una mancata riduzione delle ospedalizzazioni per BPCO do-
vrebbe indurre i decisori a porsi il dubbio dell’appropriatezza
e della qualità delle cure fornite in questo ambito.
Parole chiave: BPCO, cure primarie, epidemiologia, sistema di
informazione sulla salute.     
INTRODUCTION
Chronic Obstructive Pulmonary Disease (COPD) is
a disease state characterised by the presence of air-
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4 flow limitation due to chronic bronchitis or emphy-
sema; the airflow obstruction is generally progres-
sive; it may be accompanied by airway hyperreac-
tivity, and may be partially reversible [1].
COPD is currently the 5th cause of morbidity and
mortality in the developed world and represents a
substantial economic and social burden [2]. Earlier
surveys have yielded a varied global prevalence of
COPD ranging from 0.23% to 18.3%, the variability
being due to differences in diagnostic criteria and
epidemiologic study designs [3]. A recent large-
scale, population-based study conducted in several
different countries has estimated the prevalence of
COPD to be more than 10% among adults aged 40
years and older [4]. 
Currently 210 million people have COPD and 3
million people died of COPD in 2005. According to
new estimates for 2030, COPD is predicted to be-
come the 3rd leading cause of death [5]. Much of
the increase in COPD is associated with projected
increases in tobacco use and the exposure to smoke
from the combustion of solid fuels indoors, for heat-
ing and cooking [5].
Primary care data show that the prevalence of
COPD seems to have peaked in men, but continues
to rise in women [6], especially in the lower socio-
economic groups [7]. Throughout the course of
their disease, COPD patients experience a progres-
sive deterioration up to end-stage disease, which is
characterised by – apart from severe airway obstruc-
tion – declining performance status, multiple co-
morbidities, and severe systemic manifestations and
complications [2]. 
The actual burden of the disease in the community
is much higher, as a substantial number of patients
with COPD remain undiagnosed and, consequent-
ly, untreated [8].
The slowly progressive nature of COPD [9] means
that the disease usually remains undetected for
many years, and most patients are first identified
when they have an exacerbation. By the time
COPD is diagnosed, often 50% of lung function has
already been lost and the need for healthcare utili-
sation is high [10].
The presence of comorbidities strongly influences
the evolution of the disease and the frequency of
exacerbations, as shown in a recent systematic in-
vestigation which examined the role of concomitant
diseases in the history of COPD through the use of
standardised indices such as Charlson’s [11].
Exacerbations may cause serious morbidity, hospi-
tal admission and mortality, and strongly influence
health related quality of life of patients with COPD.
Patients with frequent exacerbations show faster de-
terioration of their health status than those with in-
frequent exacerbations [12]. Despite the impact of
exacerbations on patients’ health [13,14], many ex-
acerbations of COPD go unnoticed and patients of-
ten do not consult their physician until days or even
weeks after the onset of an exacerbation.
The burden of COPD in terms of healthcare use and
costs strongly depends on the disease severity. For
example, the costs of treating exacerbations in pri-
mary care patients with COPD increase along with
the severity of the disease: these costs are mainly at-
tributable to more physician consultations, diagnos-
tic procedures, and prescriptions for reliever med-
ication (e.g. bronchodilators, cough preparations)
[15]. Still, the majority of COPD-related healthcare
costs are generated in secondary care, and are es-
pecially due to emergency room visits and hospital
admissions [16].
The aim of this work is to report on hospital admis-
sions and related costs of hospital treatments for
COPD in the region of Puglia, Italy in the years
2005-2007.
METHODS
We analysed the Apulian hospital patient discharge
database for the years 2005-2007, selecting hospi-
tal admissions for patients resident in the region and
those transferred to and from other Italian regions.
A record of hospitalisation for COPD was selected
if the ‘Principal Diagnosis’ field of the database
contained one of the following ICD-9-CM codes:
490.xx: bronchitis not specified as acute or chronic;
491.xx: chronic bronchitis; 492.xx: emphysema;
493.xx: asthma; 494.xx: bronchiectasis; 496.xx:
chronic airway obstruction not elsewhere classified;
518.81: acute respiratory failure.
For cost analysis, the Diagnosis Related Groups
(DRG) for each hospitalisation were assessed at the
tariffs agreed by the Puglia Regional Authority on 3
October 2006, Order n. 1464 [17]. The average
weighting of the DRG produced was calculated uti-
lizing the DRG weightings indicated by the
Ministerial Decree of 27 October 2000, n. 380
[18]. To calculate the hospitalisation rate, the popu-
lation data as of 1 January 2006 from the Italian
Institute of Statistics (ISTAT) were used. 
The mean hospitalisation time was calculated using
the ratio of the sum of days spent in hospital, taken
from hospital discharge records, and the number of
admissions.
For comorbidities, secondary diagnosis fields were
examined from 1 to 5, classifying codes according
chapters in the ICD-9-CM system.
To evaluate the difference in performance between
types of patient discharge units in managing cases
of COPD, we also calculated and compared mean
hospital stay, the average weight and the average
age of patients hospitalised in pneumology, internal
medicine and in other departments.
RESULTS
In the period 2005-2007, there were 73,721 hospi-
tal admissions for COPD registered in Puglia:
25,690 in 2005, 24,153 in 2006 and 23,878 in
2007; of which 34.3% were women, with no signif-
icant variation across the three years. The most fre-
quent diagnosis was chronic bronchitis followed by
asthma.
There appears to be a negative trend in hospitalisa-




















creasing from 359.4 per 100,000 population in
2005 to 307.9 per 100,000 in 2007 (Table I). The
overall cost of COPD to hospital trusts in Puglia was
€272,293,182.85 over the 3-year period:
€265,492,164.59 for DRGs of COPD patients resi-
dent in Puglia and treated in Apulian health facili-
ties (Table II) plus €6,801,018.26 for DRGs of pa-
tients resident in Puglia but treated in health facili-
ties in other Italian regions (Table III). Non-resident
DRGs treated in Apulian facilities amounted to
€5,389,017.54 (Table IV).
Mean hospitalisation time for COPD, mean age of
patients and the average DRG weight, per depart-
ment, are shown in Table V.
The distribution of comorbidities was different
across the various departments. The majority of pa-
tients, 53.2%, in General Medicine had concomi-
tant cardiovascular pathologies while this figure
was only 43.1% in Pneumology. The second most
frequent concomitant pathology in General
Medicine was digestive diseases, 6.7%, while in
Pneumology it was another respiratory disease,
15%.
For COPD patients with acute respiratory failure,
the mean hospitalisation time, the mean patient age
and the mean DRG weight, per department, are
shown in Table VI. The most frequent comorbidities
for patients with acute respiratory failure in
Pneumology were cardiovascular disease, 31.8%,
respiratory disease, acute and chronic, 35.9%, and
metabolic disease, 11.3%; while in General
Medicine they were cardiovascular disease, 49.9%,
respiratory disease, 18.4%, and tumours, 14.9%.
TABLE I: HOSPITALISATION RATES PER 100,000 APULIAN RESIDENTS, BY YEAR AND PRINCIPAL DIAGNOSIS. PUGLIA, 
2005-2007
Diagnosis 2005 2006 2007
Hospitalised In other Hospitalised In other Hospitalised In other 
in Puglia regions in Puglia regions in Puglia regions
Bronchitis not specified 6.2 0.3 6.6 0.1 5.9 0.1
as acute or chronic
Chronic bronchitis 359.4 7.5 321.8 7.4 307.9 7.1
Emphysema 4.3 0.5 4.5 0.4 4.2 0.4
Asthma 63.5 3.4 65.5 2.9 64.8 2.9
Bronchiectasis 5.6 0.7 6.0 0.9 5.6 0.6
Chronic airway obstruction 1.0 0.1 0.6 0.0 0.4 0.1
not elsewhere classified
Acute respiratory failure 191.6 6.4 188.2 3.9 197.6 3.4
Total 631.6 189 593,2 15,6 586,4 14,6
TABLE II: EVALUATION OF DIAGNOSIS RELATED GROUPS (DRGs) FOR HOSPITALISATIONS IN PUGLIA OF COPD
PATIENTS RESIDENT IN PUGLIA, YEARS 2005-2007
Diagnosis Evaluation Year Total
2005 2006 2007
Bronchitis not specified Admissions 252 270 241 763
as acute or chronic
Cost € 378,666.80 € 437,565.29 € 373,687.03 € 1,189,919.12
Chronic bronchitis Admissions 14,619 13,103 12,538 40,260
Cost € 38,990,293.91 € 36,616,473.75 € 35,640,432.98 € 111,247,200.64
Emphysema Admissions 173 182 171 526
Cost € 539,249.61 € 629,438.25 € 576,284.00 € 1,744,971.86
Asthma Admissions 2,585 2,668 2,638 7,891
Cost € 3,247,305.11 € 3,469,986.49 € 3,209,752.01 € 9,927,043.61
Bronchiectasis Admissions 226 244 228 698
Cost € 697,580.92 € 744,569,81 € 719,021.7 € 2,161,172.43
Chronic airway obstruction Admissions 40 24 15 79
not elsewhere classified Cost € 100,431.96 € 66,987.17 € 41,625.4 € 209,044.53
Acute respiratory failure Admissions 7,795 7,662 8,047 23,504
Cost € 43,485,726.66 € 45,826,994.88 € 49,700,090.86 € 139,012,812.40
Total Admissions 25,690 24,153 23,878 73,721
































COPD is one of the most widespread health prob-
lems in the world and represents a high direct cost
for the national health services. However, because
of the high levels of comorbidities and death asso-
ciated with this chronic disease it is difficult to eval-
uate the costs of its management in hospital [19].
The use of hospital records to analyse the burden of
disease produced by hospital services and proce-
dures for COPD can be problematic. First, only a
small proportion of COPD patients are admitted to
hospital, the majority being treated at home and us-
ing at most the hospitals' outpatient services for
analysis and therapy. The accuracy of a diagnosis of
COPD can vary from hospital to hospital as not all
suspected cases undergo spirometry [20] and the
hospital patient discharge database does not record
the outcome of spirometry, blood gases analysis
and other instrument based diagnostic procedures.
Furthermore, the management databases are inade-
quate in evaluating the severity of disease and any
attempt at staging can be made only through proxy
indicators such as comorbidities and average age of
the patient.
However, hospital admission data are still important
indicators of the burden of the disease, both in
terms of the quality of the management of home
treatment and healthcare costs. Admission to hospi-
tal is almost always linked to a worsening episode,
TABLE III: EVALUATION OF DIAGNOSIS RELATED GROUPS (DRGs) FOR HOSPITALISATIONS IN OTHER REGIONS 
OF COPD PATIENTS RESIDENT IN PUGLIA, YEARS 2005-2007
Diagnosis Evaluation Year Total
2005 2006 2007
Bronchitis not specified Admissions 11 3 3 17
as acute or chronic Cost € 15,178.4 € 2,169.48 € 2,952.07 € 20,299.95
Chronic bronchitis Admissions 306 303 288 897
Cost € 712,055.71 € 753,420.51 € 736,917.83 € 2,202,394.05
Emphysema Admissions 21 15 18 54
Cost € 85,079.93 € 57,816.16 € 148,000.74 € 290,896.83
Asthma Admissions 137 117 119 373
Cost € 166,621.48 € 132,705.52 € 130,916.59 € 430,243.59
Bronchiectasis Admissions 29 35 25 89
Cost € 83,037.26 € 100,831.61 € 117,033.46 € 300,902.33
Chronic airway obstruction Admissions 5 1 4 10
not elsewhere classified Cost € 16,861.42 € 2,345.28 € 5,318.35 € 24,525.05
Acute respiratory failure Admissions 259 161 138 558
Cost € 1,526,925.19 € 1,001,694.14 € 1,003,137.13 € 3,531,756.46
Total Admissions 768 635 595 1998
Cost € 2,605,759.39 € 2,050,982.70 € 2,144,276.17 € 6,801,018.26
TABLE IV: EVALUATION OF DIAGNOSIS RELATED GROUPS (DRGs) FOR HOSPITALISATIONS IN PUGLIA OF NON-RESIDENT
COPD, YEARS 2005-2007
Diagnosis Evaluation Year Total
2005 2006 2007
Bronchitis not specified Admissions 11 5 5 21
as acute or chronic Cost € 16,827.35 € 5,623.42 € 8,157.44 € 30,608.21
Chronic bronchitis Admissions 227 230 205 662
Cost € 661,158.02 € 602,797.67 € 577,197.06 € 1,841,152.75
Emphysema Admissions 3 6 7 16
Cost € 5,975.91 € 18,579.48 € 30,213.61 € 54,769.00
Asthma Admissions 79 80 96 255
Cost € 112,039.77 € 109,784.65 € 137,996.87 € 359,821.29
Bronchiectasis Admissions 5 7 7 19
Cost € 19,097.86 € 22,968.17 € 20,900.70 € 62,966.73
Chronic airway obstruction Admissions 0 2 0 2
not elsewhere classified Cost 0 € 5,944.01 0 € 5,944.01
Acute respiratory failure Admissions 166 137 141 444
Cost € 912,449.57 € 965,909.02 € 1,155,396.96 € 3,033,755.55
Total Admissions 491 467 461 1419




















impacting on the quality of life of the patient with
COPD [21].
Regional health policies [22] are geared towards a
more efficient use of hospital care for acute cases;
however we observed no trend in the period of
study for COPD - this may be due to the lack of al-
ternative care facilities within the community or to
problems related to chronic disease in general or
COPD in particular, all of which can influence the
demand for hospitalisation. The slight reduction in
the number of admissions observed during the
study period seems a poor outcome of the strong re-
gional administrative push in promoting treatment
appropriateness and prevention of avoidable hospi-
talisation, and it cannot be ascribed to changes in
the epidemiology of disease.
While Pneumology departments more frequently
treated patients with respiratory-related problems,
General Medicine wards treated older patients and
so more pathologies.
Analysis of average DRG weight and hospital stay
do not show particular differences in performance
between the different departments except for acute
respiratory failure, which is a major cost for the
Puglia Region both within and without the Region.
The treatment of acute respiratory failure has a
much lower average DRG weight and average hos-
pital stay within non-specialised departments than
in Intensive Care which generates complex DRGs
due to the quantity of care necessary and the fre-
quent practice of tracheotomy.
In Italy there are still no national data on the preva-
lence of COPD and even the analysis of the data-
base of hospital admissions, available from the
Ministry of Health, is hampered by various prob-
lems related to inadequate updating of information
and the availability of only aggregate data. A recent
survey of a representative sample of the population
estimated the prevalence of COPD in Italy at
around 3% [23]. As already noted in other surveys
conducted in Italy, cardiovascular pathologies are
the most commonly reported comorbidities; the
high frequency highlighted in our study is to be
placed in relation to the analysis of the hospitalised
population, at increased risk of pluripathology [24].
The emergence of new healthcare needs and the
necessity to re-orientate the management of chronic
healthcare from hospitals to the community oblige
Pneumology departments and pneumologists to
play a leading role in the application of innovative
management of chronic pulmonary diseases, for
reasons of both their social-health impact and their
costs. In fact, services in the community should be
reinforced and not reduced in order to create a net-
work of facilities that ensures the maximum cost-
benefit for the health services and for patients. In ef-
fect, the network of anti-tuberculous dispensaries in
Italy was the first example of community healthcare
for a chronic disease with a strong social-health im-
pact and it should be a starting point for specialist
community healthcare for respiratory disease.
The analysis of data on hospital care, its costs and
performance may be an important indicator of how
effectively community care functions, while the
lack of reduction in admissions for COPD should
lead decision makers to question both the appropri-
ateness and quality of the care given.
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TABLE V: MEAN HOSPITALISATION TIME, AGE AND DIAGNOSIS RELATED GROUP (DRG) WEIGHT OF COPD PATIENTS, BY
DEPARTMENT
Department Average stay (days) Average age of patients (years) Average DRG weight
Pneumology 8.0 70.2 1.18
General Medicine 8.2 73.2 1.19
Other (geriatrics, paediatrics, long stay) 11.6 70.0 1.33
TABLE VI: MEAN HOSPITALISATION TIME, AGE AND DIAGNOSIS RELATED GROUP (DRG) WEIGHT OF COPD PATIENTS WITH
ACUTE RESPIRATORY FAILURE BY DEPARTMENT
Department Average stay (days) Average age of patients (years) Average DRG weight
Pneumology 11.6 72.4 1.96
General Medicine 9.6 74.1 1.45
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